01:33 , Apr 19, 2019 |  BC Innovations  |  Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
13:06 , Mar 13, 2019 |  BC Innovations  |  Distillery Therapeutics

IKKβ inhibition for tendinopathy

DISEASE CATEGORY: Musculoskeletal INDICATION: Musculoskeletal Patient sample, cell culture and mouse studies suggest inhibiting IKKβ could help treat tendinopathy. In tendon tissues samples from patients with rotator cuff disease, levels of IKKβ protein were higher...
19:19 , Jul 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Obesity Mouse studies suggest depleting microglia or inhibiting their inflammatory activity could help treat obesity. In a mouse model of obesity, depletion of microglia in the mediobasal hypothalamus with the CSF1R inhibitor PLX5622 or...
07:00 , Oct 6, 2016 |  BC Innovations  |  Targets & Mechanisms

Seeking cysteines

In settling the question of how Biogen Inc. 's Tecfidera dimethyl fumarate (DMF) acts in multiple sclerosis, a Scripps team has identified PKCθ as a key driver, sitting atop an NF-κB pathway to immunosuppression. The...
07:00 , Apr 23, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Inhibitor of κ light gene enhancer in B cells kinase α (IKKα; IKBKA; IKK1; CHUK; NFKBIKA); IKKβ (IKBKB; IKK2; NRKBIKB)

Cancer INDICATION: Cancer In vitro and mouse studies suggest the natural product (+)-ainsliadimer A could help treat cancer. In vitro, (+)-ainsliadimer A covalently bound the cysteine 46 residue of IKKα and IKKβ (Ki = 30...
07:00 , Mar 12, 2015 |  BC Innovations  |  Targets & Mechanisms

TBK1 and beyond

Biogen Idec Inc. 's partnership with Columbia University and the HudsonAlpha Institute for Biotechnology has yielded a new target in ALS - TBK1 - that provides a link between autophagy, neuroinflammation and the pathology of...
07:00 , Oct 16, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Inhibitor of k-light polypeptide gene enhancer in B cells kinase-b (IKBKB; IKK2); b-amyloid (Ab) Mouse studies suggest inhibiting IKK2 in myeloid cells...
07:00 , Jun 12, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Atherosclerosis; obesity Inhibitor of k-light polypeptide gene enhancer in B cells kinase-b (IKBKB; IKK2) Mouse studies suggest inhibiting IKBKB could help treat atherosclerosis. In a...
08:00 , Feb 3, 2014 |  BioCentury  |  Emerging Company Profile

ImStar: Neuronal pacifier

ImStar Therapeutics Inc. is using new discoveries about the physiopathology of amyotrophic lateral sclerosis to develop small molecules that block a key kinase interaction leading to immune-related neuroinflammation. The company hopes to have preclinical proof-of-concept...
07:00 , Oct 17, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

This week in techniques Approach Summary Licensing status Publication and contact information Assays & screens Virus-based in vivo RNAi screens to identify host interactions In vitro and in vivo RNAi screens to identify virus-host interactions...